- Home
- COF vs ABBV Comparison
COF vs ABBV Comparison
Compare COF & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COF | ABBV |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.8B | 400.9B |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | COF | ABBV |
|---|---|---|
| Price | $182.81 | $228.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 19 |
| Target Price | ★ $269.31 | $247.06 |
| AVG Volume (30 Days) | 5.0M | ★ 5.6M |
| Earning Date | 01-01-0001 | 04-13-2026 |
| Dividend Yield | 1.73% | ★ 3.05% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.36 |
| Revenue | N/A | ★ $61,160,000,000.00 |
| Revenue This Year | $96.05 | $11.90 |
| Revenue Next Year | $4.97 | $8.24 |
| P/E Ratio | ★ $52.03 | $96.45 |
| Revenue Growth | N/A | ★ 8.57 |
| 52 Week Low | $143.22 | $164.39 |
| 52 Week High | $259.64 | $244.81 |
Technical Indicators
Market Signals| Indicator | COF | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 30.28 | 50.66 |
| Support Level | N/A | $220.11 |
| Resistance Level | $226.76 | $229.94 |
| Average True Range (ATR) | 7.03 | 4.76 |
| MACD | -0.88 | -0.43 |
| Stochastic Oscillator | 12.02 | 42.68 |
Price Performance
Historical ComparisonAbout COF Capital One Financial Corporation
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending. Following the acquisition of Discover in 2025, the firm also has a modest personal loan business, though credit card lending provides the majority of the bank's revenue.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.